Endpoint definition
↥| Name | CD2_BENIGN_LACRIMAL |
|---|---|
| Long name | Benign neoplasm: Lacrimal gland and duct |
| Level in the ICD-hierarchy | 3 |
| First defined in version | DF2 |
| Latin name | Neoplasma benignum glandulae lacrimalis |
Benign neoplasm: Lacrimal gland and duct
choriocarcinoma: An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 19 | 15 | - |
| Unadjusted prevalence (%) | 0.01 | 0.01 | - |
| Mean age at first event (years) | 57.17 | 58.45 | - |
| Case fatality at 5-years (%) | 0.00 | 0.00 | - |
Longitudinal metrics
| All | Female | Male | |
|---|---|---|---|
| Median nb. of events per indiv. | 1.0 | 1.0 | - |
| Recurrence at 6 months (%) | 36.84 | 40.00 | - |
Survival analyses between endpoints
↥Plot
before Benign neoplasm: Lacrimal gland and duct
after Benign neoplasm: Lacrimal gland and duct
Loading survival analyses plot…
Table
Loading survival analyses table…